oral

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)

CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases,…

3 days ago

Alzheimer’s Association Statement on Oral Semaglutide Phase 3 Topline Data Release

- Results Underscore Need for Continued Research and Diverse Treatment PipelineCHICAGO, Nov. 24, 2025 /PRNewswire/ -- The Alzheimer's Association is disappointed…

2 weeks ago

COLGATE DEBUTS FIRST-EVER VISIBLE WHITE PURPLE SERUM: A GAME-CHANGER IN ORAL BEAUTY

MUMBAI, India, Nov. 18, 2025 /PRNewswire/ -- Teeth may not always be the first thing that comes to mind in…

3 weeks ago

Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors

– QTX3034 monotherapy and the QTX3034-cetuximab combination demonstrated favorable safety profiles and clear clinical proof of concept, including confirmed responses…

1 month ago

PIVOT-PO Phase 3 Data Show Tebipenem HBrs Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared…

2 months ago

Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

-   Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET -   Poster presentation on preclinical evaluation of petosemtamab…

2 months ago

Quanta Therapeutics Announces First Clinical Data Presentation for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held clinical-stage biopharmaceutical company…

2 months ago

Boehringers HERNEXEOS approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

This press release is not intended for UK and US media.  HERNEXEOS® (zongertinib tablets) has been approved based on an objective…

3 months ago

U.S. Oral Surgery Management Moves into 31st State

IRVING, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management (USOSM) – a management services organization that exclusively…

4 months ago

COLGATE DENTAL VEER ANTHEM LAUNCHED TO EMPOWER KIDS TO BE THEIR OWN HEROES OF ORAL HEALTH

Released close to Independence Day, the anthem is penned by lyricist Swanand Kirkire and composed by Micu Patel Link to…

4 months ago